These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28932894)

  • 1. Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET.
    Brendel M; Schnabel J; Schönecker S; Wagner L; Brendel E; Meyer-Wilmes J; Unterrainer M; Schildan A; Patt M; Prix C; Ackl N; Catak C; Pogarell O; Levin J; Danek A; Buerger K; Bartenstein P; Barthel H; Sabri O; Rominger A
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2239-2248. PubMed ID: 28932894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of early-phase [
    Daerr S; Brendel M; Zach C; Mille E; Schilling D; Zacherl MJ; Bürger K; Danek A; Pogarell O; Schildan A; Patt M; Barthel H; Sabri O; Bartenstein P; Rominger A
    Neuroimage Clin; 2017; 14():77-86. PubMed ID: 28138429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Amyloid positron-emission-tomography with [
    Schönecker S; Prix C; Raiser T; Ackl N; Wlasich E; Stenglein-Krapf G; Mille E; Brendel M; Sabri O; Patt M; Barthel H; Bartenstein P; Levin J; Rominger A; Danek A
    Nervenarzt; 2017 Feb; 88(2):156-161. PubMed ID: 27913818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Relevance of [
    Librizzi D; Cabanel N; Zavorotnyy M; Riehl E; Kircher T; Luster M; Hooshyar Yousefi B
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33652938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [
    Hellwig S; Frings L; Bormann T; Vach W; Buchert R; Meyer PT
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):312-323. PubMed ID: 30094462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early-Phase 18F-Florbetaben PET as an Alternative Modality for 18F-FDG PET.
    Son SH; Kang K; Ko PW; Lee HW; Lee SW; Ahn BC; Lee J; Yoon U; Jeong SY
    Clin Nucl Med; 2020 Jan; 45(1):e8-e14. PubMed ID: 31524679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study.
    Segovia F; Gómez-Río M; Sánchez-Vañó R; Górriz JM; Ramírez J; Triviño-Ibáñez E; Carnero-Pardo C; Martínez-Lozano MD; Sopena-Novales P
    J Alzheimers Dis; 2018; 65(3):765-779. PubMed ID: 30103321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers.
    Bensaïdane MR; Beauregard JM; Poulin S; Buteau FA; Guimond J; Bergeron D; Verret L; Fortin MP; Houde M; Bouchard RW; Soucy JP; Laforce R
    J Alzheimers Dis; 2016 Apr; 52(4):1251-62. PubMed ID: 27104896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coupled Imaging with [
    Chiaravalloti A; Castellano AE; Ricci M; Barbagallo G; Sannino P; Ursini F; Karalis G; Schillaci O
    Mol Imaging Biol; 2018 Aug; 20(4):659-666. PubMed ID: 29404839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic impact of [
    Zwan MD; Bouwman FH; Konijnenberg E; van der Flier WM; Lammertsma AA; Verhey FR; Aalten P; van Berckel BN; Scheltens P
    Alzheimers Res Ther; 2017 Jan; 9(1):2. PubMed ID: 28093088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Incremental Diagnostic Value of [18F]Florbetaben PET and the Pivotal Role of the Neuropsychological Assessment in Clinical Practice.
    Spallazzi M; Barocco F; Michelini G; Morelli N; Scarlattei M; Baldari G; Ruffini L; Caffarra P
    J Alzheimers Dis; 2019; 67(4):1235-1244. PubMed ID: 30689568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of molecular imaging on the diagnostic process in a memory clinic.
    Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
    Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management impact of FDG-PET in dementia: results from a tertiary center memory clinic.
    Elias A; Woodward M; Rowe CC
    J Alzheimers Dis; 2014; 42(3):885-92. PubMed ID: 24961944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.
    de Wilde A; van der Flier WM; Pelkmans W; Bouwman F; Verwer J; Groot C; van Buchem MM; Zwan M; Ossenkoppele R; Yaqub M; Kunneman M; Smets EMA; Barkhof F; Lammertsma AA; Stephens A; van Lier E; Biessels GJ; van Berckel BN; Scheltens P
    JAMA Neurol; 2018 Sep; 75(9):1062-1070. PubMed ID: 29889941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Added value of
    Ceccaldi M; Jonveaux T; Verger A; Krolak-Salmon P; Houzard C; Godefroy O; Shields T; Perrotin A; Gismondi R; Bullich S; Jovalekic A; Raffa N; Pasquier F; Semah F; Dubois B; Habert MO; Wallon D; Chastan M; Payoux P; ; Stephens A; Guedj E
    Alzheimers Dement; 2018 Mar; 14(3):293-305. PubMed ID: 29107051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study.
    Panegyres PK; Rogers JM; McCarthy M; Campbell A; Wu JS
    BMC Neurol; 2009 Aug; 9():41. PubMed ID: 19674446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes.
    Bergeron D; Beauregard JM; Guimond J; Fortin MP; Houde M; Poulin S; Verret L; Bouchard RW; Laforce R
    J Alzheimers Dis; 2016; 49(3):695-705. PubMed ID: 26484904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.
    Foster NL; Heidebrink JL; Clark CM; Jagust WJ; Arnold SE; Barbas NR; DeCarli CS; Turner RS; Koeppe RA; Higdon R; Minoshima S
    Brain; 2007 Oct; 130(Pt 10):2616-35. PubMed ID: 17704526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias.
    Taswell C; Villemagne VL; Yates P; Shimada H; Leyton CE; Ballard KJ; Piguet O; Burrell JR; Hodges JR; Rowe CC
    J Nucl Med; 2015 Oct; 56(10):1547-53. PubMed ID: 26251415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.